Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03617133 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer

Study acronym: EMBRACEII
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date changed from estimate of Apr 2021 to Dec 31, 2021 Collaborators revised (50)v6 Show 1 more changeShow less
    • Collaborators revised (50)

    See this version in full on ClinicalTrials.gov ↗

  2. Collaborators expanded, about 211 wordsv5 See this version in full on ClinicalTrials.gov ↗
  3. 3 versions Re-verified since Jan 29, 2020, no change to tracked fieldsv2-v4
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The research group on adaptive image-guided radiotherapy for locally advanced cervical carcinoma completed the protocol for the EMBRACE II study in October 2018. This study will be carried out in the next few years at the University Clinic for Radiotherapy at the Medical University of Vienna and other international partner institutes. EMBRACE II builds on the findings of the current EMBRACE study. These are already implemented in everyday clinical practice in order to further improve the accuracy of the entire therapy of cervical carcinomas, using state-of-the-art techniques of tele- and brachytherapy. The aim of the EMBRACE II study is to maintain and enhance the excellent local tumor control as well as the nodal and systemic control for all tumor stages while minimizing the adverse reaction rates for all affected organs (rectum, sigmoid, urinary bladder, and vagina) to increase the quality of life of patients with cervical carcinomas.
Trial Details
NCT Number NCT03617133
Lead Sponsor Medical University of Vienna
Collaborators: Universitaire Ziekenhuizen KU Leuven, Aarhus University Hospital, Rigshospitalet, Denmark, Odense University Hospital, North Estonia Medical Centre, Institut Bergonié, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital Heidelberg, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Oslo University Hospital, Institute of Oncology Ljubljana, Complejo Hospitalario de Navarra, Hospital Clinic of Barcelona, Skane University Hospital, Region Örebro County, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Radiotherapiegroep, Leiden University Medical Center, Maastro Clinic, The Netherlands, UMC Utrecht, The Netherlands Cancer Institute, Radboud University Medical Center, Catharina Ziekenhuis Eindhoven, Erasmus Medical Center, Cambridge University Hospitals NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, The Christie NHS Foundation Trust, University Hospitals Coventry and Warwickshire NHS Trust, University Hospitals Bristol and Weston NHS Foundation Trust, Royal Marsden NHS Foundation Trust, Cross Cancer Institute, McGill University, Princess Margaret Hospital, Canada, Tom Baker Cancer Centre, Loyola University Chicago, M.D. Anderson Cancer Center, University of Pittsburgh, Pamela Youde Nethersole Eastern Hospital, Tuen Mun Hospital, Post Graduate Institute of Medical Education and Research, Chandigarh, Tata Memorial Centre, Chulalongkorn University, Siriraj Hospital, Liverpool Hospital, Sydney, Maisonneuve-Rosemont Hospital, National Cancer Institute, Slovakia, Institut Català d'Oncologia, Ludwig-Maximilians - University of Munich, Mount Vernon Cancer Centre, St Thomas' Hospital, London
Conditions Uterine Cervical Neoplasms
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov